Zhimeng Biopharma EN | 简体
Zhimeng Biopharma
  • Home
  • About Us
  • People
    • Leadership Team
    • Management Team
    • Scientific Advisors
  • Pipeline
  • News
  • Investors
  • Join Us
  • Contact

News

Feb 21, 2019

Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019

Nov 09, 2018

Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco

Get in touch

Contact Us About Us Leadership Team Management Team Scientific Advisors
AstraCrux Clinical Trial and Consulting is a unique company where law overlaps with clinical science.
Quick Links
  • About Us
  • Contact Us
  • Join Us
  • Pipeline
  • Leadership Team
  • Management Team
  • Scientific Advisors
Recent News
  • Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019
  • Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco

© 2019 Zhimeng Biopharma. All Rights Reserved. Powered By 720Bio 备案号:沪ICP备18045542号-1 | 沪公网安备 31011502011190号

© 2019 Zhimeng Biopharma. All Rights Reserved. Powered By 720Bio